Receptor.ai

Receptor.ai is a private, pre-revenue AI-native biotechnology company offering an end-to-end computational drug discovery platform. Its core technology is a modular, agentic AI-driven ecosystem with three distinct platforms for small molecules, peptides, and proximity inducers, each designed to tackle specific modality challenges like cryptic pocket targeting and multiparametric optimization. The company operates a platform/services business model, partnering with biopharma clients to generate novel, IP-free drug candidates, as evidenced by its published case studies, though it does not appear to have an internal therapeutic pipeline advancing through clinical trials.

A multiplatform AI ecosystem with three modality-specific platforms (Small Molecules, Peptides, Proximity Inducers) powered by tailored Agentic AI workflows. Capabilities include cryptic pocket identification, de novo binder design, multiparametric optimization (QuorumMap), ADMET prediction (ADMETiQ), and prediction of protein-protein interaction structures.

Receptor.ai operates in a highly competitive field with numerous AI-driven drug discovery players, including Exscientia, Insilico Medicine, and Recursion, as well as tech giants like Google's Isomorphic Labs. Its differentiation lies in its explicit focus on three distinct therapeutic modalities and its claim of targeting cryptic pockets and complex PPIs.